Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc. today announced Paul M. Martha, M.D. has been named to the newly-created position of Chief Medical Officer, reporting to William Heiden, President and Chief Executive Officer. In his new position, Dr. Martha will be responsible for managing the clinical development of Elixir’s product candidates. Dr. Martha will be focused initially on overseeing the Phase III program for GlinsunaTM (mitiglinide calcium hydrate) and MetglunaTM (mitiglinide plus metformin), which are being developed for the treatment of Type 2 diabetes, as well advancing the ghrelin antagonist, ghrelin agonist and SIRT programs through clinical development.

Back to news